EGRX News and Press, Eagle Pharmaceuticals Inc. From 12/15/21

Eagle Pharmaceuticals (EGRX +13.1%) announced that the FDA has approved its abbreviated new drug application (“ANDA”) for vasopressin. The regulatory nod for the therapeutic equivalent of Vasostrict follows the recent legal battle won by Eagle (NASDAQ:EGRX) over Par Pharmaceutic...

-- Company is first to file an ANDA referencing Vasostrict ® , which had total U.S. sales of $786 million in 2020 -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Food and Drug Administrat...

As a new COVID-19 variant (omnicron) raises concerns worldwide, we think it could be wise to scoop up the shares of quality pharmaceutical stocks GlaxoSmithKline (GSK), Teva Pharmaceutical (TEVA), and Eagle Pharmaceuticals (EGRX) that look undervalued at their current price levels. These stoc...

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present virtually at the Piper Sandler 33 rd Annual Healthcare Conference ...

Image source: The Motley Fool. Eagle Pharmaceuticals, inc (NASDAQ: EGRX) Q3 2021 Earnings Call Nov 9, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Eagle Pharmaceuticals, inc (EGRX) Q3 2021 Earnings Call Transcrip...

Eagle Pharmaceuticals, Inc. (EGRX) Q3 2021 Earnings Conference Call November 9, 2021, 08:30 AM ET Company Participants Lisa Wilson - Investor Relations Scott Tariff - Chief Executive Officer Brian Cahill - Chief Financial Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald...

Eagle Pharmaceuticals (NASDAQ:EGRX): Q3 Non-GAAP EPS of $0.56 misses by $0.27; GAAP EPS of -$0.43 beats by $0.01. Revenue of $39.85M (-20.2% Y/Y) misses by $6.07M. Press Release “We are preparing for two significant product launches, vasopressin and PEMFEXY™, expected within the...

Q3 2021 net loss was $0.43 per basic and diluted share and adjusted non-GAAP net income was $0.57 per basic and $0.56 per diluted share Expect to receive approval for Abbreviated New Drug Application (“ANDA”) for vasopressin; December 15, 2021 GDUFA date Received...

Eagle Pharmaceuticals (NASDAQ:EGRX) is scheduled to announce Q3 earnings results on Tuesday, November 9th, before market open. The consensus EPS Estimate is $0.83 (-29.1% Y/Y) and the consensus Revenue Estimate is $45.92M (-8.0% Y/Y). Over the last 2 years, EGRX has beaten EPS estimates 63% o...

California State Court hands Endo and other opioid producers a temporary win in liability trial. Tentative ruling directs manufacturers to file a statement of decision within 30 days. Ruling likely takes away major liability in the country's biggest state at least for a while. ...